Barclays maintains RVL Pharmaceuticals at Overweight, PT $2.00

A Barclays analyst maintained RVL Pharmaceuticals (NASDAQ: RVLP) at Overweight and a price target of $2.00 from a prior price target of $3.00.
Prior to this rating, RVL Pharmaceuticals had 4 buy ratings, 1 hold ratings, and 0 sell ratings.
For consensus analyst estimates and price targets on RVL Pharmaceuticals, click here. For more news on RVL Pharmaceuticals, click here.
RVL Pharmaceuticals's stock price closed at $0.870. They are up 0% in the last month and down -32.030% in the last 12 months.
According to Investing Pro, RVL Pharmaceuticals's fair value is $0.937, an upside of 7.706%. RVL Pharmaceuticals's fair value comes with a high degree of uncertainty, according to InvestingPro.
Check out RVL Pharmaceuticals's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or